{"id":745600,"date":"2017-01-31T16:00:00","date_gmt":"2017-01-31T16:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\/"},"modified":"2025-11-07T01:26:41","modified_gmt":"2025-11-07T06:26:41","slug":"european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\/","title":{"rendered":"European Commission Approves KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations"},"content":{"rendered":"<p class=\"bwalignc\">       Approval Based on Data Showing Improved Overall Survival and        Progression-Free Survival with KEYTRUDA Compared to Chemotherapy     <\/p>\n<p class=\"bwalignc\">       First Anti-PD-1 Therapy Approved in Europe for Previously Untreated        Patients with Metastatic NSCLC     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the European Commission has approved KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), the company\u2019s anti-PD-1 therapy, for the first-line<br \/>\n      treatment of metastatic non-small cell lung cancer (NSCLC) in adults<br \/>\n      whose tumors have high PD-L1 expression (tumor proportion score [TPS] of<br \/>\n      50 percent or more) with no EGFR or ALK positive tumor mutations.\n    <\/p>\n<p>\n      \u201cThe approval of KEYTRUDA as a first treatment instead of chemotherapy<br \/>\n      for patients who express high levels of PD-L1 has the potential to<br \/>\n      transform the way metastatic non-small cell lung cancer is treated,\u201d<br \/>\n      said&nbsp;Dr. Roy Baynes, senior vice president, head of clinical<br \/>\n      development, and chief medical officer, Merck Research Laboratories. \u201cWe<br \/>\n      are committed to ensuring that patients in Europe \u2013 who are in need of<br \/>\n      new treatment options \u2013 are able to quickly gain access to KEYTRUDA.\u201d\n    <\/p>\n<p>\n      The approval is based on phase 3 data which demonstrated superior<br \/>\n      overall survival (OS) and progression-free survival (PFS) with KEYTRUDA<br \/>\n      compared to chemotherapy, the current standard of care for advanced<br \/>\n      NSCLC. The approval allows marketing of KEYTRUDA in all 28 EU member<br \/>\n      states plus Iceland, Lichtenstein and Norway, at the approved dose of<br \/>\n      200 mg every three weeks until disease progression or unacceptable<br \/>\n      toxicity. In August 2016, KEYTRUDA (pembrolizumab) (2 mg\/kg every three<br \/>\n      weeks) was approved in Europe for previously-treated patients with<br \/>\n      locally advanced or metastatic NSCLC whose tumors express PD-L1 (TPS of<br \/>\n      1 percent or more) and who have received at least one prior chemotherapy<br \/>\n      regimen.\n    <\/p>\n<p>\n      \u201cThe data demonstrate that KEYTRUDA provided meaningful improvements in<br \/>\n      survival versus the current standard of care in patients whose tumors<br \/>\n      express high levels of PD-L1,\u201d said Dr. Luis Paz-Ares, chair of the<br \/>\n      medical oncology department, Hospital Universitario Doce de Octubre,<br \/>\n      Madrid, Spain. \u201cThese findings supporting the approval also provide<br \/>\n      further rationale for biomarker testing in order to identify those<br \/>\n      patients more likely to benefit the most from treatment with KEYTRUDA.\u201d\n    <\/p>\n<p>\n      <b>About KEYNOTE-024<\/b>\n    <\/p>\n<p>\n      The European Commission\u2019s approval is based on data from KEYNOTE-024, a<br \/>\n      randomized, open-label, phase 3 study evaluating KEYTRUDA monotherapy at<br \/>\n      a fixed dose of 200 mg compared to standard of care platinum-containing<br \/>\n      chemotherapy (pemetrexed+carboplatin, pemetrexed+cisplatin,<br \/>\n      gemcitabine+cisplatin, gemcitabine+carboplatin, or<br \/>\n      paclitaxel+carboplatin) for the treatment of patients with both squamous<br \/>\n      and non-squamous metastatic NSCLC. The study enrolled 305 patients who<br \/>\n      had not received prior systemic chemotherapy treatment for their<br \/>\n      metastatic disease and whose tumors had high PD-L1 expression with no<br \/>\n      EGFR or ALK aberrations. The primary endpoint was PFS; additional<br \/>\n      efficacy outcome measures were OS and objective response rate (ORR).\n    <\/p>\n<p>\n      In the study, KEYTRUDA reduced the risk of disease progression or death<br \/>\n      by 50 percent compared to chemotherapy (HR, 0.50 [95% CI, 0.37, 0.68];<br \/>\n      p&lt;0.001). The median PFS for KEYTRUDA was 10.3 months (95% CI, 6.7-not<br \/>\n      reached) compared to 6.0 months for chemotherapy (95% CI, 4.2-6.2). At<br \/>\n      six months and 12 months, respectively, 62 percent and 48 percent of<br \/>\n      patients treated with KEYTRUDA were alive and had no disease progression<br \/>\n      compared to 50 percent and 15 percent of those receiving chemotherapy.\n    <\/p>\n<p>\n      Additionally, KEYTRUDA resulted in a 40 percent reduction in the risk of<br \/>\n      death compared to chemotherapy (HR, 0.60 [95% CI, 0.41, 0.89]; p=0.005);<br \/>\n      this finding includes the 66 patients (43.7%) on the chemotherapy arm<br \/>\n      who crossed over in-study to receive KEYTRUDA once their cancer had<br \/>\n      progressed; median OS was not reached in either group. The OS rate at<br \/>\n      six months and 12 months, respectively, was 80 percent and 70 percent in<br \/>\n      patients treated with KEYTRUDA compared to 72 percent and 54 percent in<br \/>\n      those receiving chemotherapy.\n    <\/p>\n<p>\n      Further, ORR was 45 percent for patients receiving KEYTRUDA<br \/>\n      (pembrolizumab) (95% CI, 37-53), including six complete responses,<br \/>\n      compared to 28 percent with chemotherapy (95% CI, 21-36), including one<br \/>\n      complete response.\n    <\/p>\n<p>\n      The safety analysis supporting the European approval of KEYTRUDA was<br \/>\n      based on 2,953 patients with advanced melanoma or NSCLC across four<br \/>\n      doses (2 mg\/kg every three weeks, 200 mg every three weeks, or 10 mg\/kg<br \/>\n      every two or three weeks) in studies KEYNOTE-001, KEYNOTE-002,<br \/>\n      KEYNOTE-010 and KEYNOTE-024 combined. The most common adverse reactions<br \/>\n      (\u226510%) with KEYTRUDA were fatigue (24%), rash (19%), pruritus (17%),<br \/>\n      diarrhea (12%), nausea (11%) and arthralgia (10%). The majority of<br \/>\n      adverse reactions reported were of Grade 1 or 2 severity. The most<br \/>\n      serious adverse reactions were immune-related adverse reactions and<br \/>\n      severe infusion-related reactions.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single use vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b> <b>Indications and Dosing in the U.S.<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a dose of 2 mg\/kg every three weeks until disease<br \/>\n      progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the first-line treatment of patients with<br \/>\n      metastatic non-small cell lung cancer (NSCLC) whose tumors have high<br \/>\n      PD-L1 expression [tumor proportion score (TPS) \u226550%] as determined by an<br \/>\n      FDA-approved test, with no EGFR or ALK genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with metastatic<br \/>\n      NSCLC whose tumors express PD-L1 (TPS \u22651%) as determined by an<br \/>\n      FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA<br \/>\n      (pembrolizumab).\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) can cause hypophysitis. Hypophysitis occurred<br \/>\n      in 17 (0.6%) of 2799 patients receiving KEYTRUDA, including Grade 2<br \/>\n      (0.2%), 3 (0.3%), and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs<br \/>\n      and symptoms of hypophysitis (including hypopituitarism and adrenal<br \/>\n      insufficiency). Administer corticosteroids and hormone replacement as<br \/>\n      clinically indicated. Withhold KEYTRUDA for Grade 2; withhold or<br \/>\n      discontinue for Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. Thyroiditis occurred in 16 (0.6%) of 2799 patients<br \/>\n      receiving KEYTRUDA, including Grade 2 (0.3%) thyroiditis. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. For suspected immune-mediated adverse reactions, ensure<br \/>\n      adequate evaluation to confirm etiology or exclude other causes. Based<br \/>\n      on the severity of the adverse reaction, withhold KEYTRUDA and<br \/>\n      administer corticosteroids. Upon improvement to Grade 1 or less,<br \/>\n      initiate corticosteroid taper and continue to taper over at least 1<br \/>\n      month. Based on limited data from clinical studies in patients whose<br \/>\n      immune-related adverse reactions could not be controlled with<br \/>\n      corticosteroid use, administration of other systemic immunosuppressants<br \/>\n      can be considered. Resume KEYTRUDA when the adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), exfoliative dermatitis, bullous pemphigoid, rash<br \/>\n      (1.4%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis,<br \/>\n      vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising<br \/>\n      in a patient with inflammatory foci in brain parenchyma.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) can cause severe or life-threatening<br \/>\n      infusion-related reactions, which have been reported in 6 (0.2%) of 2799<br \/>\n      patients. Monitor patients for signs and symptoms of infusion-related<br \/>\n      reactions, including rigors, chills, wheezing, pruritus, flushing, rash,<br \/>\n      hypotension, hypoxemia, and fever. For Grade 3 or 4 reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 8% of 682 patients<br \/>\n      with metastatic NSCLC. The most common adverse event resulting in<br \/>\n      permanent discontinuation of KEYTRUDA was pneumonitis (1.8%). Adverse<br \/>\n      reactions leading to interruption of KEYTRUDA occurred in 23% of<br \/>\n      patients; the most common (\u22651%) were diarrhea (1%), fatigue (1.3%),<br \/>\n      pneumonia (1%), liver enzyme elevation (1.2%), decreased appetite<br \/>\n      (1.3%), and pneumonitis (1%). The most common adverse reactions<br \/>\n      (occurring in at least 20% of patients and at a higher incidence than<br \/>\n      with docetaxel) were decreased appetite (25% vs 23%), dyspnea (23% vs<br \/>\n      20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>About Lung Cancer<\/b>\n    <\/p>\n<p>\n      Lung cancer, which forms in the tissues of the lungs, usually within<br \/>\n      cells lining the air passages, is the leading cause of cancer death<br \/>\n      worldwide. Each year, more people die of lung cancer than die of colon,<br \/>\n      breast, and prostate cancers combined. The two main types of lung cancer<br \/>\n      are non-small cell and small cell. NSCLC is the most common type of lung<br \/>\n      cancer, accounting for about 85 percent of all cases. The five-year<br \/>\n      survival rate for patients suffering from highly advanced, metastatic<br \/>\n      (Stage IV) lung cancers is estimated to be two percent.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 400 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51501803&amp;newsitemid=20170131006176&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=20217c729c3d29b4dae8aad52859a078\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For over a century, Merck has been a global health care leader working<br \/>\n      to help the world be well. Merck is known as MSD outside the United<br \/>\n      States and Canada. Through our prescription medicines, vaccines,<br \/>\n      biologic therapies, and animal health products, we work with customers<br \/>\n      and operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51501803&amp;newsitemid=20170131006176&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=5959e3857e7133b925ba592823768bec\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51501803&amp;newsitemid=20170131006176&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=80117d74b1f89de248037c8078f52522\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51501803&amp;newsitemid=20170131006176&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=8f337f63ebdf776c82f7977316859894\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51501803&amp;newsitemid=20170131006176&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=b21ccc8b637e0bc70e7fc36419d17cbb\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51501803&amp;newsitemid=20170131006176&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=031fac75be1ef3aeed6d4cd1db1524d2\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51501803&amp;newsitemid=20170131006176&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=0ab3f5b61cc94ba5482c81c123a63951\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51501803&amp;newsitemid=20170131006176&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=e01ef0dfeca225bb22fbaed8dc6bfc16\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/a><br \/>\n<b>&nbsp;and<br \/>\n      Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51501803&amp;newsitemid=20170131006176&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=2cd8208da0ff30ed4ab3497fe3b74ef7\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170131006176r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       For Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Courtney        Ronaldo, 908-236-1108<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tumor mutations. \u201cThe approval of KEYTRUDA as a first treatment instead of chemotherapy for patients who express high levels of PD-L1 has the potential to transform the way metastatic non-small cell lung cancer is treated,\u201d said&nbsp;Dr. Roy Baynes, senior vice president, head of clinical development, and chief medical officer, Merck Research Laboratories. \u201cWe are committed to ensuring that patients in Europe \u2013 who are in need of new treatment options \u2013 are able to quickly gain access to KEYTRUDA.\u201d The approval is based on phase 3 data which demonstrated superior overall survival (OS) and<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289],"class_list":["post-745600","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>European Commission Approves KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"European Commission Approves KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tumor mutations. \u201cThe approval of KEYTRUDA as a first treatment instead of chemotherapy for patients who express high levels of PD-L1 has the potential to transform the way metastatic non-small cell lung cancer is treated,\u201d said&nbsp;Dr. Roy Baynes, senior vice president, head of clinical development, and chief medical officer, Merck Research Laboratories. \u201cWe are committed to ensuring that patients in Europe \u2013 who are in need of new treatment options \u2013 are able to quickly gain access to KEYTRUDA.\u201d The approval is based on phase 3 data which demonstrated superior overall survival (OS) and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\\\/\",\"name\":\"European Commission Approves KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-01-31T16:00:00+00:00\",\"dateModified\":\"2025-11-07T06:26:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"European Commission Approves KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"European Commission Approves KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\/","og_locale":"en_US","og_type":"article","og_title":"European Commission Approves KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tumor mutations. \u201cThe approval of KEYTRUDA as a first treatment instead of chemotherapy for patients who express high levels of PD-L1 has the potential to transform the way metastatic non-small cell lung cancer is treated,\u201d said&nbsp;Dr. Roy Baynes, senior vice president, head of clinical development, and chief medical officer, Merck Research Laboratories. \u201cWe are committed to ensuring that patients in Europe \u2013 who are in need of new treatment options \u2013 are able to quickly gain access to KEYTRUDA.\u201d The approval is based on phase 3 data which demonstrated superior overall survival (OS) and","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:41+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\/","name":"European Commission Approves KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-01-31T16:00:00+00:00","dateModified":"2025-11-07T06:26:41+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-have-high-pd-l1-expression-with-no-egfr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"European Commission Approves KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"7ca6921e-315f-4c87-b327-5be172bf5c2a","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/European-Commission-Approves-KEYTRUDA-pembrolizumab-for-First-Line-Treatment-of-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer-N-8VF0U.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745600\/revisions"}],"predecessor-version":[{"id":3674967,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745600\/revisions\/3674967"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745600"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}